AbClon Inc. (KOSDAQ:174900)

South Korea flag South Korea · Delayed Price · Currency is KRW
34,450
+4,400 (14.64%)
Nov 20, 2025, 3:30 PM KST
14.64%
Market Cap573.74B
Revenue (ttm)3.80B
Net Income (ttm)-16.23B
Shares Out19.09M
EPS (ttm)-896.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume799,894
Average Volume386,373
Open32,000
Previous Close30,050
Day's Range31,650 - 34,900
52-Week Range6,810 - 34,900
Beta1.17
RSI81.33
Earnings Daten/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 174900
Full Company Profile

Financial Performance

In 2024, AbClon's revenue was 2.34 billion, a decrease of -18.67% compared to the previous year's 2.88 billion. Losses were -16.42 billion, 27.2% more than in 2023.

Financial Statements

News

There is no news available yet.